alanine has been researched along with Angor Pectoris in 12 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ranolazine was given as an intravenous bolus followed by continuous infusion; the mean total dose was 32." | 1.30 | Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. ( Bagger, JP; Bøtker, HE; Nielsen, TT; Thomassen, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Colaco, K | 1 |
| Lee, KA | 1 |
| Akhtari, S | 1 |
| Winer, R | 1 |
| Welsh, P | 1 |
| Sattar, N | 1 |
| McInnes, IB | 1 |
| Chandran, V | 1 |
| Harvey, P | 1 |
| Cook, RJ | 1 |
| Gladman, DD | 1 |
| Piguet, V | 1 |
| Eder, L | 1 |
| Scirica, BM | 1 |
| Morrow, DA | 1 |
| Cannon, CP | 1 |
| de Lemos, JA | 1 |
| Murphy, S | 1 |
| Sabatine, MS | 1 |
| Wiviott, SD | 1 |
| Rifai, N | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Thuesen, L | 1 |
| Nielsen, TT | 7 |
| Thomassen, A | 7 |
| Bagger, JP | 7 |
| Henningsen, P | 6 |
| Bøtker, HE | 3 |
| Møller, N | 1 |
| Ovesen, P | 1 |
| Mengel, A | 1 |
| Schmitz, O | 1 |
| Orskov, H | 1 |
| Vanhanen, I | 1 |
| Håkanson, E | 1 |
| Jorfeldt, L | 1 |
| Svedjeholm, R | 1 |
| Thygesen, K | 1 |
| Tashchuk, VK | 1 |
| Shumakov, VA | 1 |
| Malinovskaia, IE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
1 trial available for alanine and Angor Pectoris
| Article | Year |
|---|---|
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Diseas | 2007 |
11 other studies available for alanine and Angor Pectoris
| Article | Year |
|---|---|
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis.
Topics: Adult; Alanine; Angina Pectoris; Apolipoproteins B; Arthritis, Psoriatic; Cardiovascular Diseases; C | 2021 |
Beneficial effect of a low-fat low-calorie diet on myocardial energy metabolism in patients with angina pectoris.
Topics: Alanine; Angina Pectoris; Cardiac Pacing, Artificial; Citrates; Citric Acid; Dietary Fats; Energy In | 1984 |
Insulin resistance in microvascular angina (syndrome X)
Topics: Alanine; Angina Pectoris; Basal Metabolism; Blood Glucose; C-Peptide; Chest Pain; Coronary Circulati | 1993 |
Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Topics: Acetanilides; Aged; Alanine; Angina Pectoris; Blood Pressure; Citric Acid; Coronary Circulation; Cor | 1997 |
Intravenous aspartate infusion after a coronary operation: effects on myocardial metabolism and hemodynamic state.
Topics: Alanine; Angina Pectoris; Aspartic Acid; Blood Glucose; Cardiac Catheterization; Coronary Artery Byp | 1998 |
Effects of glutamate on exercise tolerance and circulating substrate levels in stable angina pectoris.
Topics: Alanine; Angina Pectoris; Blood Chemical Analysis; Citrates; Citric Acid; Electrocardiography; Exerc | 1990 |
Cardiac metabolic effects of heparin differentiate between patients with normal and stenotic coronary arteries.
Topics: Alanine; Angina Pectoris; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Fatty Acids, Nones | 1990 |
[Apex cardiography in the hemodynamic assessment of patients with unstable stenocardia].
Topics: Alanine; Angina Pectoris; Angina, Unstable; beta-Alanine; Cardiac Pacing, Artificial; Echocardiograp | 1989 |
Antianginal and cardiac metabolic effects of low-dose glucose infusion during pacing in patients with and without coronary artery disease.
Topics: Alanine; Angina Pectoris; Blood Glucose; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Ele | 1989 |
Altered global myocardial substrate preference at rest and during pacing in coronary artery disease with stable angina pectoris.
Topics: Adult; Alanine; Angina Pectoris; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Fatty Acids | 1988 |
Metabolic and hemodynamic effects of nicardipine during pacing-induced angina pectoris.
Topics: Alanine; Angina Pectoris; Blood Pressure; Cardiac Catheterization; Cardiac Pacing, Artificial; Citra | 1987 |